Coya Therapeutics (NASDAQ: COYA) reports $4.2 million ALS trial payment

Rhea-AI Filing Summary

Coya Therapeutics, Inc. received a $4.2 million milestone payment under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories SA.

The payment was triggered when the first patient was dosed in Coya’s ALSTARS clinical trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The first patient dosing in ALSTARS was previously announced on December 9, 2025, marking a key development step for the COYA 302 ALS program.

Insights

Biotech equity analyst

Coya records $4.2 million milestone tied to ALS trial progress.

Coya Therapeutics reported receiving a $4.2 million milestone payment under its Development and License Agreement with Dr. Reddy’s Laboratories. The trigger was dosing the first patient in the ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis (ALS), a key operational step for the program.

This payment represents non-product revenue linked to a specific development milestone, rather than recurring sales, and is tied directly to clinical progress. It also signals that the partnered ALS trial has advanced to active patient dosing as of its announcement on December 9, 2025, an important stage in drug development where safety and efficacy data can begin to accumulate.

Further financial or clinical impact will depend on future milestones and trial outcomes under the same agreement, which are not detailed in this disclosure. Subsequent company communications may outline additional milestones, data readouts from ALSTARS, or other payments related to COYA 302’s development in ALS.

false 0001835022 0001835022 2025-12-16 2025-12-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2025

Coya Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-41583		85-4017781
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5850 San Felipe St., Suite 500
Houston, Texas		77057
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 800 587-8170

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		COYA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On December 16, 2025, Coya Therapeutics, Inc. (the “Company”) received a $4.2 million milestone payment under the Development and License Agreement, dated December 5, 2023 (the “DRL Development Agreement”), by and amongst the Company, Dr. Reddy’s Laboratories Ltd. and its affiliate, Dr. Reddy’s Laboratories SA. The milestone payment was triggered by dosing of the first patient in the Company’s ALSTARS trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS), which was announced on December 9, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						COYA THERAPEUTICS, INC.
Date: December 17, 2025				By:		/s/ Arun Swaminathan Ph.D.
						Arun Swaminathan Ph.D. Chief Executive Officer

FAQ

What did Coya Therapeutics (COYA) disclose in this report?

Coya Therapeutics, Inc. disclosed that it received a $4.2 million milestone payment under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories SA.

How much was the milestone payment Coya Therapeutics (COYA) received and what triggered it?

The company received a $4.2 million milestone payment, which was triggered by dosing the first patient in its ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis (ALS).

What is the ALSTARS trial mentioned by Coya Therapeutics (COYA)?

The ALSTARS trial is a clinical study conducted by Coya Therapeutics evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).

Who are Coya Therapeutics partners under the Development and License Agreement?

The Development and License Agreement is by and amongst Coya Therapeutics, Inc., Dr. Reddy’s Laboratories Ltd. and its affiliate, Dr. Reddy’s Laboratories SA.

When was the milestone-triggering event for Coya Therapeutics (COYA) announced?

The dosing of the first patient in the ALSTARS trial, which triggered the milestone payment, was announced on December 9, 2025.

What therapeutic area is targeted by COYA 302 in Coya Therapeutics ALSTARS trial?

COYA 302 in the ALSTARS trial is being evaluated for the treatment of amyotrophic lateral sclerosis (ALS).